GLUCOSE- dextrose anhydrous injection, solution
Baxter Healthcare Company

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

50% and 70% glucose injection

Health Care Professional Letter

Important Prescribing Information

December 18, 2024

Subject: Temporary importation of 50% and 70% Glucose Injection from the United Kingdom to address drug shortages

Dear Healthcare Professional,

To prevent a drug shortage of large volume parenteral fluid drug products, Baxter Healthcare Corporation (Baxter) is coordinating with the U.S. Food and Drug Administration (FDA) to temporarily import 50% Glucose Injection 3,000 mL and 70% Glucose Injection 500 mL from Baxter's manufacturing facility in Thetford, United Kingdom. FDA has not approved these products manufactured by Baxter's Thetford facility.

You may be provided with additional letters for other imported products you receive. Please read each letter in its entirety because each letter may contain different, product-specific information.

At this time, no other entity except Baxter is authorized by the FDA to import or distribute these products in the United States.

Effective immediately, and during this temporary period, Baxter will offer the following imported products:

Product name and description	Size	Product code	Bags per carton	NDC code of a single bag
50% Glucose Injection	3,000 mL	FKB0257B	4	0338-9787-01
70% Glucose Injection	500 mL	FKB0273B	20	0338-9785-01

It is important to note the following:

- Dextrose injection products contain the hydrated form of glucose. The Glucose injection products contain the anhydrous form of glucose. While both Dextrose and Glucose injection products are manufactured from chemically identical glucose ingredients, the difference between the hydrous and anhydrous forms results in Glucose injection products NOT being equivalent in caloric content, osmolality, and specific gravity to Dextrose injection products (see table below).

	Dextrose 50%	Glucose 50%
Caloric content (kcal/L)	1,710	2,000
Osmolarity (mOsm/L)	2,520	2,775
Specific Gravity	1.170	1.185

- Baxter has worked proactively to prepare the Training Materials For Baxter Medical Information page (Baxter Resources for Products Authorized for Temporary Importation) to help support customers:
  - Webinars:
    - Dextrose, USP vs Glucose – What are the differences?
    - How to operationalize Glucose for Compounding?
  - Step by Step guide to adding Glucose 50% into ExactaMix and Abacus

- The Glucose 50% product is the equivalent of 55% Dextrose USP, and the Glucose 70% product is the equivalent of 77% Dextrose USP.

- Protocols, order entry, and compounding systems will need to be adjusted.

- After opening the carton or box, the bags should be inspected visually to confirm there is no visible particulate matter or bag defects, such as leaks. Container integrity is imperative to ensure sterility of the products listed in the table above. Parenteral drug products should be inspected visually for particulate matter and bag defects prior to administration, whenever solution or container permits.
  USE A NEW BAG IF PARTICULATES ARE VISIBLE OR IF THE IV BAG CONTAINS A LEAK.

- The imported products are not intended for direct patient administration. When compounding with the imported products, check for compatibility of all additives and stability of the resulting preparation.

- The imported products' administration port system is fully compatible with Baxter sets marketed in the United States.

Baxter has worked proactively to prepare the Training Materials for Baxter Medical Information page (https://meded.baxter.com/hurricane-helene-clinical-resources/baxter-resources-for-products-authorized-for-temporary-importation)

- **The imported products do not contain barcodes on the unit label.** Institutions should manually input the product into their systems to ensure that barcode systems do not provide incorrect information when the product is scanned. Alternative procedures should be followed to ensure that the correct drug product and concentration are being used in all systems and processes and administered to individual patients.

- 50% Dextrose for Injection USP and 70% Dextrose for Injection USP are available only by prescription in the U.S. However, the imported products 50% Glucose Injection and 70% Glucose Injection do not have the statement "Rx only" on the labeling.

Additional key differences in the labeling between the FDA-approved product and the imported products are stated in the product comparison table at the end of this letter as follows:

Table 1 Key differences between FDA-approved 70% Dextrose Injection USP, imported 70% Glucose Injection and imported 50% Glucose Injection
Table 2 Label images of FDA-approved 70% Dextrose Injection USP, imported 70% Glucose Injection and imported 50% Glucose Injection

Please refer to the UK prescribing information as follows for any pharmaceutical calculations of a final product that uses concentrated Glucose Injection:

- 70% Glucose Injection (click here) – Local product name in the UK: Glucose 70% w/v Concentrate for solution for infusion
- 50% Glucose Injection (click here) – Local product name in the UK: Glucose 50% w/v Concentrate for solution for infusion

Please refer to the FDA-approved prescribing information for 70% Dextrose Injection USP:

- 70% Dextrose Injection USP (click here)

Reporting Adverse Events or Product Quality Issues

To report **adverse events** associated with these imported products, please call Baxter at 1-866-888-2472, or fax: 1-800-759-1801. Adverse events or quality problems experienced with the use of these imported products may also be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax:

- Complete and submit the report **Online**: www.fda.gov/medwatch/report.htm
- **Regular mail or Fax**: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 (1-800-332-0178).

To report **product quality issues** associated with these imported products, please contact Baxter Product Surveillance through Baxter Product Feedback Portal (https://productfeedback.baxter.com/).

Please refer to the UK prescribing information as follows for any pharmaceutical calculations of a final product that uses concentrated Glucose injection:

- 70% Glucose Injection (click https://mhraproducts4853.blob.core.windows.net/docs/6be6cb79cc56be57f99cfd218cfbd1b34bca8047)) – Local product name in the UK: Glucose 70% w/v Concentrate for solution for infusion
- 50% Glucose Injection (click

https://mhraproducts4853.blob.core.windows.net/docs/6d79a27acece3f48020b83e2b3716a2353b6f8b3) – Local product name in the UK: Glucose 50% w/v Concentrate for solution for infusion

Please refer to the FDA-approved prescribing information for the 70% Dextrose Injection USP:

- 70% Dextrose Injection USP (click https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0332f34a-7038-47cc-ba59-d55cad6b73ca)

Reporting Adverse Events or Product (Quality Issues)

To report adverse events associated with these imported products, please call Baxter at 1-866-888-2472, or fax: 1-800-759-1801. Adverse events or quality problems experienced with the use of these imported products may also be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax:

- Complete and submit the report **Online**: www.fda.gov/medwatch/report.htm
- **Regular mail or Fax**: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 (1-800-332-0178).

To report **product quality issues** associated with these imported products, please contact Baxter Product Surveillance through Baxter Product Feedback Portal (https://productfeedback.baxter.com/).

If you have any questions about the information contained in this letter or the use of the imported products, please contact Baxter's Medical Information Service at 1-800-933-0303.

To place an order, please contact Baxter's Center for Service by calling 1-888-229-0001.

Sincerely,

Lee Ann Schuette

Electronically signed by: Lee Ann Schuette
Reason: I approve this document
Date: Dec 18, 2024 15:40 CST

Lee Ann Schuette
Vice President, Global and US Marketing IV solutions, Clinical Nutrition, Pharmacy Tools
Baxter Healthcare Corporation

Table 1 Key differences between FDA-approved 70% Dextrose Injection USP, imported 70% Glucose Injection and imported 50% Glucose Injection

	US FDA-approved product	Imported product from the UK	Imported product from the UK
Product name	70% Dextrose Injection USP	Glucose 70% **w/v Concentrate for solution for infusion**	Glucose 50% **w/v Concentrate for solution for infusion**
Label Volume	2,000 mL	**500 mL**	**3,000 mL**
Indications	Dextrose Injection is indicated as a source of calories when mixed with amino acids or other compatible intravenous fluids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.	Glucose 70% w/v is for use in admixtures to provide temporary relief from the symptoms of increased intracranial pressure and hypoglycaemic coma and is also indicated for the supplementation of energy in parenteral nutrition.	Glucose 50% w/v is for use in admixtures to provide temporary relief from the symptoms of increased intracranial pressure and hypoglycaemic coma and is also indicated for the supplementation of energy in parenteral nutrition.
Active ingredients	Each 1,000 mL contains 700 g Dextrose Hydrous	Each 1,000 mL contains 700 g **Anhydrous** Glucose equivalent to **770 g** Dextrose Hydrous	Each 1,000 mL contains 500 g **Anhydrous** Glucose equivalent to **550 g** Dextrose Hydrous
Caloric content	Each 1,000 mL contains **2,380 kcal** (calculated)	Each 1,000 mL contains **2,800 kcal** (calculated)	Each 1,000 mL contains **2,000 kcal** (calculated)
Additional information	pH is 4.0 (3.2 to 6.5) Osmolarity **3,530 mOsm/L** (calc)	pH is 3.2 – 5.5 Osmolarity **3,885 mOsm/L**	pH is 3.2 – 5.5 Osmolarity **2,775 mOsm/L**
Storage conditions	Store at room temperature 25°C/77°F. Protect from freezing.	Do not store above 25°C/77°F	Do not store above 25°C/77°F
Container type	VIAFLEX (PVC)	VIAFLEX (PVC)	VIAFLEX (PVC)
Administration port closures	Pull off port protector (blue color) 	Twist-off port protector (blue color) 	Twist-off port protector (blue color) 

Table 2 Label images of FDA-approved 70% Dextrose Injection USP, imported 70% Glucose Injection and imported 50% Glucose Injection

US FDA-approved product	Imported product from the UK	Imported product from the UK
70% Dextrose Injection USP	Glucose 70% **w/v Concentrate for solution for infusion**	Glucose 50% **w/v Concentrate for solution for infusion**
Label Color: Blue (fully). Barcode not shown.	Label Color: Black	Label Color: Black
		

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL



Container Label

Code B0257 3000 ml

Baxter Logo

Glucose 50% w/v
Concentrate for solution for infusion

VIAFLEX container Hypertonic
Free from bacterial endotoxins

Formula per 1000 ml
Anhydrous Glucose
Water for Injections
HCl for pH adjustment
Megajoules (approx.)

500 g

8.4 (2000 kcal)

50%

Dilute before use – bulk source container
Not for direct intravenous infusion

For use under medical supervision
For intravenous use following dilution under aseptic conditions
Check compatibility with other admixture components before use
Keep out of the sight and reach of children
Do not store above 25°C

Do not use unless solution is clear and container is undamaged
Single use only Do not store partially used containers
Discard any unused portion, waste materials and all associated devices
Do not administer simultaneously with blood or, before or after, using the same transfusion equipment
Discontinue infusion if adverse reaction occurs

Baxter Healthcare Ltd
Caxton Way Thetford
Norfolk IP24 3SE UK

LOT EXP

POM

PL 00116/0271
TH-35-01-934



Carton Label

Baxter Logo
Code FKB0257B

Glucose 50% w/v
Concentrate for
solution for infusion

Hypertonic

Do not store above 25°C
Keep out of sight and reach of children

Baxter Healthcare Ltd
Caxton Way, Thetford, Norfolk, IP24 3SE, UK

POM

LOT: EXP:

4 x 3000 ml
(≈15.5 kg)

50%

PL 00116/0271
TH-25-02-116

Baxter Logo
Code FKB0257B

Glucose 50% w/v
Concentrate for
solution for infusion

Hypertonic

POM

4 x 3000 ml
(≈15.5 kg)

50%

LOT: EXP:

Container Label

1 –

-

2-

-

3-

-

4-

Code B0273 500 ml

Baxter Logo

Glucose 70% w/v
Concentrate for solution for infusion

VIAFLEX container Hypertonic
Free from bacterial endotoxins

Formula per 1000 ml
Anhydrous Glucose
Water for Injections
HCl for pH adjustment
Megajoules (approx.)

700 g

11.8 (2800 kcal)

70%

Dilute before use – bulk source container
Not for direct intravenous infusion

For use under medical supervision
For intravenous use following dilution under aseptic conditions
Check compatibility with other admixture components before use
Keep out of the sight and reach of children
Do not store above 25°C
Do not use unless solution is clear and container is undamaged
Single use only Do not store partially used containers
Discard any unused portion, waste materials and all associated devices
Do not administer simultaneously with blood or, before or after, using the same transfusion equipment
Discontinue infusion if adverse reaction occurs

Baxter Healthcare Ltd
Caxton Way Thetford
Norfolk IP24 3SE UK

Lot Expiry

POM
PL 00116/0272
TH-35-01-931

-1

-

-2

-

-3

-

-4



Carton Label

Baxter Logo
Code FKB0273B

Glucose 70% w/v
Concentrate for
solution for infusion

Hypertonic

Do not store above 25°C
Keep out of sight and reach of children

Baxter Healthcare Ltd
Caxton Way, Thetford, Norfolk, IP24 3SE, UK

LOT: EXP:

20 x 500 ml
(≈15.0 kg)

70%

POM
PL 00116/0272
TH-25-02-117

Baxter Logo
Code FKB0273B

Glucose 70% w/v
Concentrate for
solution for infusion

Hypertonic

20 x 500 ml
(≈15.0 kg)

70%

POM
PL 00116/0272

LOT: EXP:

GLUCOSE
dextrose anhydrous injection, solution

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	**Item Code (Source)**	NDC:0338-9787
Route of Administration	INTRAVENOUS		

Active Ingredient/Active Moiety		
Ingredient Name	**Basis of Strength**	**Strength**
DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK)	DEXTROSE MONOHYDRATE	55 g in 100 mL

Inactive Ingredients	
Ingredient Name	**Strength**
WATER (UNII: 059QF0KO0R)	
HYDROCHLORIC ACID (UNII: QTT17582CB)	

Packaging				
#	**Item Code**	**Package Description**	**Marketing Start Date**	**Marketing End Date**
1	NDC:0338-9787-04	4 in 1 CARTON	10/18/2024	
1	NDC:0338-9787-01	3000 mL in 1 BAG; Type 0: Not a Combination Product		

Marketing Information			
Marketing Category	**Application Number or Monograph Citation**	**Marketing Start Date**	**Marketing End Date**
Unapproved drug for use in drug shortage		10/18/2024	

GLUCOSE
dextrose anhydrous injection, solution

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	**Item Code (Source)**	NDC:0338-9785
Route of Administration	INTRAVENOUS		

Active Ingredient/Active Moiety		
Ingredient Name	**Basis of Strength**	**Strength**
DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK)	DEXTROSE MONOHYDRATE	77 g in 100 mL

Inactive Ingredients

Ingredient Name	Strength
WATER (UNII: 059QF0KO0R)	
HYDROCHLORIC ACID (UNII: QTT17582CB)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0338-9785-20	20 in 1 CARTON	10/18/2024	
1	NDC:0338-9785-01	500 mL in 1 BAG; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Unapproved drug for use in drug shortage		10/18/2024	

Labeler - Baxter Healthcare Company (005083209)

Establishment

Name	Address	ID/FEI	Business Operations
Baxter Healthcare Ltd		221478644	ANALYSIS(0338-9787, 0338-9785) , LABEL(0338-9787, 0338-9785) , MANUFACTURE(0338-9787, 0338-9785) , PACK(0338-9787, 0338-9785) , STERILIZE(0338-9787, 0338-9785)

Revised: 12/2024 Baxter Healthcare Company